PT
Parvus Therapeutics develops proprietary peptide‑MHC (pMHC) nanomedicine drug candidates that induce antigen‑specific regulatory T cells (Tregs) in patients. By generating disease‑specific Tregs in vivo, the platform aims to halt autoimmune attacks and restore organ‑specific immune tolerance without broadly suppressing immunity. The company advances these candidates through clinical trials and monetizes them as prescription therapies for autoimmune diseases.
Updated 2 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- Parvus Therapeutics develops proprietary peptide‑MHC (pMHC) nanomedicine candidates that induce antigen‑specific regulatory T cells in patients. These engineered Tregs restore organ‑specific immune tolerance, halting autoimmune attacks while preserving normal immune function. The platform targets a range of autoimmune diseases with a disease‑specific, immune‑modulating approach.